Beijing Scitop Bio Tech Co Ltd
Beijing Scitop Bio-tech Co., Ltd. researches, develops, produces, and sells probiotic, postbiotics, and microecologival preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women's health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy … Read more
Beijing Scitop Bio Tech Co Ltd (300858) - Total Liabilities
Latest total liabilities as of September 2025: CN¥114.58 Million CNY
Based on the latest financial reports, Beijing Scitop Bio Tech Co Ltd (300858) has total liabilities worth CN¥114.58 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Beijing Scitop Bio Tech Co Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Beijing Scitop Bio Tech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Beijing Scitop Bio Tech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Beijing Scitop Bio Tech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NVE Corporation
NASDAQ:NVEC
|
USA | $1.78 Million |
|
Vietnam Construction and Import Export JSC
VN:VCG
|
Vietnam | ₫18.95 Trillion |
|
Kolon Life Science Inc
KQ:102940
|
Korea | ₩295.72 Billion |
|
Tokmanni Group Oyj
HE:TOKMAN
|
Finland | €1.19 Billion |
|
Saratoga Investment Corp
NYSE:SAR
|
USA | $783.76 Million |
|
Solus Advanced Materials Co Ltd
KO:336370
|
Korea | ₩1.08 Trillion |
|
Latitude Group Holdings Ltd
AU:LFS
|
Australia | AU$6.72 Billion |
|
Turaco Gold Ltd
AU:TCG
|
Australia | AU$2.07 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Beijing Scitop Bio Tech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing Scitop Bio Tech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing Scitop Bio Tech Co Ltd (2015–2024)
The table below shows the annual total liabilities of Beijing Scitop Bio Tech Co Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥126.03 Million | +63.46% |
| 2023-12-31 | CN¥77.10 Million | -17.97% |
| 2022-12-31 | CN¥93.99 Million | +28.17% |
| 2021-12-31 | CN¥73.33 Million | +10.01% |
| 2020-12-31 | CN¥66.66 Million | +0.78% |
| 2019-12-31 | CN¥66.14 Million | -8.02% |
| 2018-12-31 | CN¥71.91 Million | +27.71% |
| 2017-12-31 | CN¥56.30 Million | -21.46% |
| 2016-12-31 | CN¥71.69 Million | -45.64% |
| 2015-12-31 | CN¥131.89 Million | -- |